Purpose To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods COPD patients with forced expiratory volume in 1 s (FEV1)≤ 50% predicted and≥ …

Background Fluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting
beta 2-agonist (ICS/LABA), recently approved as once-daily maintenance therapy for COPD …

BACKGROUND: Resting inspiratory capacity (IC) reflects static hyperinflation in chronic
obstructive pulmonary disease (COPD). This study compared the effects of formoterol and …

Background: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled
corticosteroids does not appear to be as effective as similar treatment of asthma. It seems …

This study evaluated the safety and efficacy of arformoterol and formoterol over 6-months in
subjects with COPD. In a multi-center, 6-month randomized, double-blind, double-dummy …

Lung function in chronic obstructive pulmonary disease (COPD) can be improved acutely by
oral corticosteroids and bronchodilators. Whether clinical improvement can be maintained …

Several studies have suggested that anticholinergics are at least equal to or may be
superior to beta agonists in the treatment of stable COPD. However, since most previous …

While decline in lung function over time is a natural consequence of the aging process of
adults, such decline is dramatically accelerated in patients with chronic obstructive …

Clinical trials of a combination therapy of an inhaled corticosteroid, fluticasone propionate
(FP), with a long-acting β2-agonist, salmeterol (Sal), have demonstrated a greater …

Study objective To evaluate the impact of a week-long course of inhaled albuterol compared
with ipratropium on expiratory peak flow, exercise performance, and dyspnea in patients …